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Abstract: The skin is a complex organ that has devised numerous strategies, such as physical,
chemical, and microbiological barriers, to protect the host from external insults. In addition, the skin
contains an intricate network of immune cells resident to the tissue, crucial for host defense as well as
tissue homeostasis. In the event of an insult, the skin-resident immune cells are crucial not only for
prevention of infection but also for tissue reconstruction. Deregulation of immune responses often
leads to impaired healing and poor tissue restoration and function. In this review, we will discuss
the defensive components of the skin and focus on the function of skin-resident immune cells in
homeostasis and their role in wound healing.
Keywords: skin resident immune cells; skin immune responses; inflammation; wound healing;
impaired wound healing; scarring
1. Introduction
The skin is a complex organ, crucial for maintaining important functions for host physiology such
as preventing fluid loss, stabilizing body temperature and relaying sensory inputs [1,2]. In addition,
it harbors a highly specialized immunological niche crucial for the maintenance of tissue homeostasis,
defense, and repair. In this review, we will discuss the structure of the skin and its intrinsic defensive
mechanisms, with a focus on the skin-resident immune cells and their contributions to tissue repair.
2. Skin Structure
The skin is structured into three layers: the epidermis, the dermis, and subcutaneous fat tissue.
The epidermis, the outermost layer of the skin, is subdivided into the stratum corneum, stratum
lucidum, stratum granulosum, and stratum basale. The stratum corneum contains corneocytes, which
are terminally differentiated keratinocytes. These cells are continuously replenished by keratinocytes
localized in the stratum basale [1]. The stratum lucidum is a thin, clear layer of dead keratinocytes.
Instead of keratin, keratinocytes in the stratum lucidum contain eleidin, a clear intracellular protein,
which gives this layer its transparent appearance. The stratum granulosum is a thin layer between the
stratum lucidum and stratum basale. Keratinocytes in the stratum granulosum contain cysteine- and
histidine-rich granules, which bind keratin filaments together [2]. The stratum basale contains basal
keratinocytes, immune cells such as Langerhans cells and T cells, and melanocytes that provide the
skin with pigmentation.
Beneath the epidermis is the dermis, which is further categorized into papillary and reticular
sub-layers. In humans, the papillary dermis forms extensions that reach out to the epidermis and contain
capillaries that facilitate the transport of nutrients [3]. Reticular dermis contains skin appendages
such as hair follicles, sebaceous glands, and sweat glands. The reticular dermis is significantly thicker
than the papillary dermis due to the dense concentration of collagenous and reticular fibers that are
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interwoven within this layer. Both dermal layers house fibroblasts, myofibroblasts, and immune cells
such as macrophages, lymphocytes, and mast cells. Fibroblasts synthesize an extracellular matrix
consisting of collagen, proteoglycans, and elastic fibers that provide the structural integrity of the
dermis [4].
Underlying the dermis is the subcutaneous fat. This layer consists of fibrocytes and adipocytes
and is rich in proteoglycans and glycosaminoglycans, which confer mucus-like properties to the
layer [5]. Skin adipose tissue stores energy in the form of fatty acids and functions as an endocrine
organ important for glucose homeostasis and lipid metabolism [6–8]. This layer also produces a variety
of mediators such as growth factors, adipokines, and cytokines, and contains multiple immune cells [9].
In addition, the subcutaneous fat serves as an insulating layer for the body, as fat is a poor conductor
of heat.
Murine models are commonly used in dermatological research. These models are of great value
and mimic many pathological aspects observed in human skin disorders. However, it is important to
note that there are differences in the skin structure between mice and human. The thickness of murine
epidermis is thinner than that of humans’, which depending on the area of the body, is between six
and 32 layers [10]. The epithelial architecture of human skin contains rete ridges, which are extensions
that project into the underlying tissue, and do not exist in murine skin [11]. In contrast to humans,
the murine dermis lack sweat glands, excluding the mammary glands in female mice. Furthermore,
mice contain a dermal muscular layer, also known as the panniculus carnosus, which is absent in
humans [10]. The skin of other animals such as pigs more closely resembles that of humans [12],
so these animals are increasingly employed in experimental settings. However, murine models are still
widely used due to easy access and lower costs and have proved effective for the study of inflammatory
diseases of the skin.
3. The Skin as an Immune Organ
One of the main functions of the skin is to protect the host from invasion, and it does so
by employing physical barriers, biomolecules, and an intricate network of resident immune and
non-immune cells and skin structures. Furthermore, in the absence of a challenge, resident immune
cells promote skin physiological functions. Below we will describe the strategies used by the skin to
defend and protect the host, and their contributions to tissue homeostasis.
3.1. Physical Barriers
The barrier function of the epidermis is mainly mediated by corneocytes in the stratum corneum.
These cells are organized in a “bricks and mortar” manner, interspersed by lipids such as ceramides,
cholesterol, and free fatty acids [13]. Each corneocyte contains a lipid envelope linked to keratin
filament bundles that fill the intracellular compartments of the corneocyte, thus strengthening its
rigidity [14]. The stratum corneum is composed of three layers and it is both an outside-in barrier to
prevent the entry of foreign substances and microorganisms, and an inside-out barrier to prevent water
loss [15].
The formation of the physical barrier of the skin function depends on junction adhesion molecules
and tight junction proteins. Disruptions in the expression or function of these components will result in
improper barrier formation or skin disorders. Junctional adhesion molecules (JAMs), claudins, zonula
occludins-1 (ZO-1), and occludins are found in epidermal layers. Claudin-1, claudin-7, and JAM-A are
found in all layers of the human epidermis [16], while claudin-1, claudin-12, and JAM-A are ubiquitous
in murine epidermal layers [17,18]. The importance of tight junction proteins in skin function was
demonstrated by Furuse et al., who showed that deletion of claudin-1 in mice led to death shortly after
birth as a result of cutaneous defects ultimately leading to significant loss of fluids [19].
Impairment of the components of the skin’s physical barriers can contribute to inflammatory
conditions in the skin. For example, the skin of patients with atopic dermatitis exhibits reduced
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expression levels of ZO-1 and claudin-1 [20], and knockdown of claudin-1 in mice induces a psoriasis-like
condition [21].
3.2. Biomolecules of the Skin
Antimicrobial peptides (AMPs) and lipids are the main classes of biomolecules that participate in
skin defense by disrupting bacterial membranes [22–24].
AMPs are amphipathic peptides and are expressed constitutively or induced after cell activation
in response to inflammatory or homeostatic stimulation. The most thoroughly studied AMP families
in human skin are the defensins and the cathelicidins, which are produced by a variety of cells in the
skin such as keratinocytes, fibroblasts, dendritic cells, monocytes, and macrophages, and sweat and
sebaceous glands [22,23]. AMPs are produced as propeptides and become active after proteolytic
cleavage. In contrast to defensin family members, which are produced by distinct genes, there is only
one gene associated with cathelicidins (cathelicidin antimicrobial peptide—CAMP) [25]. A number
of active peptides can be generated via proteolytic cleavage of the inactive CAMP product, but the
most studied cathelicidin is LL-37 [26]. AMPs may act synergistically and have broad activity against
microbial species [27,28]. A recent study suggests certain AMPs activity may be pathogen-specific [28].
Recently, due to increased resistance to antibiotics, a focus of active research has been the evaluation of
AMPs as therapeutics against infections [22].
Interestingly, AMPs have roles in modulating host immune responses. Human LL-37 was shown
to induce differentiation of monocyte-derived dendritic cells, subsequent cytokine production, and
expression of the co-stimulatory molecule CD86 [29]. LL-37 and β-defensins can also serve as alarmins
for keratinocytes by inducing their proliferation and migration [30]. Furthermore, human LL-37
exerts its alarmin effects on immune cells in a synergistic manner with other inflammatory mediators,
such as IL-1β [31]. Human α- and β-defensins serve as chemoattractants for activated neutrophils,
memory and naïve T cells and immature dendritic cells [32], while β-defensins 3 and 4 can recruit
monocytes and macrophages [33]. The murine version ofβ-defensin 2 induces dendritic cell maturation
by upregulating the expression of co-stimulatory molecules and the antigen presentation molecule
MHCII [34].
In addition, AMP functions have been associated with the processes of aging and memory [26,32,35].
Interestingly, LL-37 has been shown to exert proangiogenic effects and may also play a role in tissue
repair [36].
Lipids such as sphingomyelin, glucosylceramides, and phospholipids are intermediate molecules,
readily converted into sphingosine and dihydrosphingosine, which exert antimicrobial activity against
certain bacterial strains such as Staphylococcus aureus, Streptococcus pyogenes, Micrococcus leutus, and
Proprionibacterium acnes [37]. These lipids are stored in lamellar bodies found in corneocytes in the
stratum corneum [38].
Sebocytes residing in the sebaceous glands produce sebum, which is rich in lipids such as
triacylglycerol, wax esters, non-esterized fatty acids, and squalene. While the functions of sebum
are not fully understood, there is a consensus that sebum serves as a “seal” for the hair follicles,
thus preventing entry of microbes into the deeper layers of the skin. Intriguingly, a previous study
demonstrated that the AMP dermcidin is expressed by sebocytes, suggesting that sebum exerts
defensive functions [39]. Furthermore, sebum can be further processed into free fatty acids by skin
commensal bacteria [40,41], and in humans, sebum-derived free fatty acids induce β-defensin 2
expression by sebocytes, further suggesting that sebaceous glands serve an innate defensive role [42].
3.3. pH of the Skin
The pH of human skin is 5.4-5.9, which makes the skin an inhospitable environment for potential
pathogens [43,44]. Furthermore, the dramatic difference in pH levels between the skin and the blood
(pH = 7.4) serves as a secondary defensive mechanism in the event that microbes breach the skin tissue
and enter the circulation. There are various ways that the skin maintains a low pH.
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Filaggrin, a filament-associated protein that binds keratin fibers, is broken down into histidine,
which is further processed by histidase, expressed by corneocytes into the acidic metabolite
trans-urocanic acid [45]; this has been implicated in the acidification of the stratum corneum [46]. Fatty
acids produced in the stratum corneum also alter the acidity of the skin [41,44]. In addition, sweat
glands produce acidic electrolytes and lactic acid, which lowers the pH of the skin [47] and promotes
epidermal turnover [48].
Furthermore, the physiological pH of the skin is hospitable for commensal bacteria such as
Staphylococcus epidermidis, preventing pathogenic strains such as Staphylococcus aureus from establishing
infections in the host [49,50].
3.4. Immune Cells of the Skin
Skin-resident immune cells promote tissue function in homeostasis and act as sentinels by actively
sampling environmental antigens. Both myeloid and lymphoid cell subsets are found in the skin in
steady state (Table 1). Some of these resident immune cells migrate to lymph nodes to either induce
peripheral tolerance to tissue self-antigens or initiate robust immune responses. In the event of a
challenge, such as infections or tissue injury, immune cells resident in the skin and those infiltrating
from the periphery interact to create an intricate defense network to resolve the insult and restore the
tissue to its original state. In this section we will describe the functions of myeloid and lymphoid cell
subsets that are resident to the skin.
Table 1. Summary of the skin’s immune cells. The location of each immune cell type in the skin
tissue and their functions during homeostasis, inflammation, and wound healing are described. N/D:
not defined.
Immune Cell
Type Location in Skin
Functions During
Homeostasis Inflammatory Functions
Functions during
Wound Healing
Langerhans cells
and dDCs
Langerhans cells:
Epidermis
dDCs: Papillary
dermis
Sampling of environmental
antigens
Migrate to lymph nodes to
induce tolerance to
self-antigens [51]
Control of
commensal-specific T cells in
the skin [52]
Migration to lymph nodes to
induce adaptive immune
responses to specific antigens
Induce T cell responses
Produce pro-inflammatory
cytokines and chemokines to
recruit peripheral immune cells
Migrate to draining lymph
nodes to prime adaptive
responses
Promote angiogenesis,
re-epithelialization,
formation of granulation
tissue, and growth factor
production [53]
Macrophages/
monocyte-derived
macrophages
Papillary and
reticular dermis
Hair follicle
regeneration/maintenance
[54]
Phagocytosis of cellular
debris
Produce cytokines, chemokines
to recruit peripheral immune
cells
Inflammatory macrophages
produce inflammatory cytokines
(IL-1β, TNFα, IL-6)
Phagocytosis of pathogenic
agents and necrotic debris
Reparative macrophages
produce growth factors
(VEGF, TGFβ) and
regulatory cytokines (IL-10)
Give rise to de novo
fibroblasts and induces their
proliferation [55]
Expression of MMPs during
tissue remodeling
Activation of myofibroblasts
[56]
Mast cells Papillary andreticular dermis N/D
Produce inflammatory
mediators involved in allergic
responses and asthma, and
recruitment of immune cells
Produce inflammatory cytokines
and secrete histamine during
contact-hypersensitivities
Induce collagen production
(fibrosis) from fibroblasts
[57–60]
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Table 1. Cont.
Immune Cell
Type Location in Skin
Functions During
Homeostasis Inflammatory Functions
Functions during
Wound Healing
Eosinophils Reticular dermis N/D
Defense against parasites
Degranulation; release of EPO,
MBP, EPX/EDN, and ECP
Infiltrates the skin tissue during
eosinophilic dermatoses [61]
N/D
Neutrophils Reticular dermis N/D (not abundant inhealthy skin)
Phagocytosis of invading
pathogens
Release of NETs (NETosis) to
immobilize pathogens
Production and secretion of
coagulation factor XII to induce
NETosis [62]
Release
chemoattractants to recruit other
neutrophils to inflamed sites [63]
Secretion of laminin 5 β-3 to
induce keratinocyte
adhesion [64]
Responsive to VEGF and
induce angiogenesis [65,66]
αβ T
lymphocytes
CD8+: Epidermis
CD4+:
Epidermis and
papillary dermis
Sentinels that can recruit
other lymphocytes to
the skin
Found to localize around
hair follicles, perhaps to
control commensal
populations in the
proximity [67]
Induces antiviral state in the
skin through IFNγmechanism
T effectors produce cognate
cytokines (i.e., IFNγ, IL-4, IL-17
Tregs suppress inflammatory
monocytes and other
autoreactive immune cells
Resolution of wound
inflammation through
Treg-mediated control of
inflammatory monocytes
[68]
γδ T
lymphocytes
(DETCs and
dermal)
DETCs:
Epidermis
Other γδ T cells:
Papillary dermis
Secretion of KGF and IGF-1
to maintain keratinocyte
populations
Migrates to draining lymph
nodes after sensing stressed
keratinocytes; antitumor
immunity [69]
Produce IL-17 to induce
β-defensin expression from
keratinocytes
Protective against cutaneous
S. aureus infection [70]
Involved in disorders such as
psoriasis [71]
Secretion of KGFs and IGF-1
to induce expansion of the
epidermis [72]
Non-γδ
CD1-restricted
lymphocytes
Papillary and
reticular Dermis N/D
Involved in defense against
extracellular pathogens
Suppress autoreactive cell
activity in systemic lupus
erythematosus
iNKT cells may be involved
in wound healing by
controlling inflammatory
neutrophil populations [73]
B lymphocytes Reticular Dermis N/D
Involved in delayed-type
hypersensitivity reactions
Involved in cutaneous
autoimmune diseases via
production of autoantibodies
specific to components of the
skin [74,75]
IL-10-producing Bregs suppress
autoreactive lymphocyte
activation
N/D
Non-immune
cells (i.e.,
keratinocytes
and fibroblasts)
Epidermis and
reticular dermis
Contribute to barrier
function of the skin
Produce collagen network to
provide structural integrity
Produce inflammatory cytokines
during disease (i.e., psoriasis),
osmotic stress, or irradiation
[76,77]
Produce AMPs in response to
bacterial detection [78–80]
Migrate to close wound
(re-epithelialization) and
restore barrier function
[7,81]
Synthesize collagen fibers
and other extracellular
matrix components in the
wound bed
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3.4.1. Myeloid Cells
Skin-resident myeloid cells include Langerhans cells, dermal dendritic cells, macrophages, mast
cells, and eosinophils. Neutrophils are rarely found in healthy skin and thus are not “skin-resident
cells.” However, neutrophils populate the skin in inflammatory conditions and after a wound, and
they will be discussed in the wound healing sections of this review.
Skin-resident myeloid cells contribute to skin homeostasis by secreting growth factors needed for
the survival of keratinocytes, fibroblasts, and endothelial cells. In addition, they maintain optimal
tissue function by phagocytosing debris and apoptotic cells, supporting vasculature integrity, and
promoting tolerance.
In inflammatory conditions, myeloid cells respond immediately and produce pro-inflammatory
mediators that drive the activation of cells in the local vicinity and infiltration of the affected site by
peripheral immune cells. Skin myeloid cells also serve as a liaison between the innate and adaptive
immune system.
Langerhans Cells
Langerhans cells (LCs) are the sole myeloid cell type in the epidermis. Phenotypically, LCs are
characterized by high expression of MHCII and the presence of langerin+ Birbeck granules [51,82].
LC maintenance depends on keratinocyte-derived IL-34 [82–85], one of the ligands for the colony
stimulating factor-1 receptor (CSF-1R). CSF-1R is constitutively expressed on LCs and global deletion
of this receptor results in a total lack of LCs [85–87]. CSF1 is dispensable for LC maintenance as
CSF1 knockout mice retain their LC populations [87]. LCs are absent in mice deficient in inhibitor of
DNA binding 2 (Id2) [88], or Runt-related transcription factor 3 (Runx3) [89]. Both Id2 and Runx3 are
involved in TGFβ signaling [88,89], and TGFβ deficiency also results in the complete loss of LCs.
LCs are derived from two sources, the extra-embryonic yolk sac and fetal liver monocytes;
so far, there are no functional attributes unique to each niche [90]. LCs renew from a local
progenitor cell [91], as shown for the first time by Merad et al., via bone marrow chimeric mice
in which donor CD45.2+ bone marrow cells were injected into lethally irradiated CD45.1+ recipient
mice. After reconstitution and BrdU administration, LCs in the recipient mice were of host origin
(CD45.1+), and incorporated BrdU, indicating that LCs are self-replenishing during homeostasis [91,92].
In inflammatory conditions, bone-marrow-derived cells are also able to give rise to short-lived or
long-lived LCs in an IL-34-independent manner [85,93]. Long-lived bone-marrow-derived LCs are
Id2-dependent [87,94].
In homeostasis, LCs anchor themselves within the epidermis through interactions between
epithelial cell adhesion molecules (EpCAM) or E-cadherin expressed on LCs and E-cadherin expressed
by keratinocytes [51,95,96]. Furthermore, autocrine and paracrine TGFβ signaling restricts LCs in the
epidermis by regulating the expression of E-cadherin on LCs [97,98], and increases phagocytic behavior
in LCs during steady state [99]. While anchored, LCs sample antigens and, upon activation, they can
extend their processes from the cell body outward to the stratum corneum or below toward the stratum
basale [51]. LCs participate in tight junction formation and thus can sample the microenvironment
without damaging the barrier [51].
LCs are migratory cells and continually travel to the skin draining lymph nodes to promote
tolerance in homeostasis [93] or to initiate adaptive immune responses [100–102]. To migrate from
the epidermis to local lymphatic vessels, LCs disengage the adhesion interaction between E-cadherin
and EpCAM/E-cadherin. The release of E-cadherin is mediated by β-catenin, which is associated
with the intracellular tail of E-cadherin and provides a link between the adhesion molecule and the
cytoskeleton [103]. LCs express matrix metalloprotease 9 (MMP9), which allows for the restructuring
of the dermal collagen network to create a path for LC migration toward the lymphatic vessel [88].
Inhibition of MMP9 activity reduces LC migration from murine and human epidermal sheets [104].
The migration of LCs (and also of dermal dendritic cells) through the dermis is mediated via CXCR4
signaling after binding to its cognate chemokine CXCL12, produced by dermal fibroblasts [105].
Int. J. Mol. Sci. 2019, 20, 1811 7 of 53
In the presence of inflammatory mediators and other activators such as pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), LCs upregulate
co-stimulatory molecules and migrate from the epidermis en masse to the draining lymph nodes,
where they prime adaptive immune responses in a manner equivalent to that of conventional dendritic
cells [51,106–109]. TGFβ signaling is disrupted during inflammation, thus also promoting LC migration
from the epidermis [97]. LCs are professional antigen-presenting cells and activate both CD8+ cytotoxic
T lymphocytes and CD4+ helper T lymphocytes. In humans, efficient antigen presentation by LCs is
dependent upon caveolin-1, a scaffold protein that serves a multitude of functions including transport of
lipids, signal transduction, and membrane trafficking [110,111]. LCs can also exert immunoregulatory
and tolerogenic functions [51,112,113]. They were shown to promote tolerance to keratinocyte antigens
in the skin by promoting the expansion of desmoglein 3-specific T regulatory cells [74], while LC
depletion led to the formation of anti-desmoglein 3 antibodies resulting in dermatitis in mice [75].
However, LCs are also known to play roles in various skin diseases such as psoriasis, atopic
dermatitis, and non-melanoma skin tumors [114–116].
Dermal Dendritic Cells
Dendritic cells that reside in the dermis are known as dermal dendritic cells (dDCs). In a similar
manner to LCs, dDCs migrate to the lymph nodes, and are professional antigen-presenting cells
efficient at priming adaptive immune responses [117,118]. It was recently shown that dDCs can induce
tolerance to topically applied antigens encountered in the hair follicles [119].
Unlike LCs, all dDCs are derived from progenitors originating from the bone marrow, with
replenishment occurring roughly every seven days [120,121]. The two main subsets of dDCs are the
conventional dendritic cell type 1 (cDC1) and the conventional dendritic cell type 2 (cDC2) [122,123].
Murine cDC1s express langerin (CD207), low levels of the fractalkine receptor CX3CR1, the chemokine
receptor XCR1, and CD103 (ITGAE), but do not express the myeloid marker CD11b. cDC2s are
the most abundant subtype of dDCs in murine skin and express CD11b, CD301b, also known as
macrophage galactose-type C-type lectin 2 (MGL2), low levels of langerin [121], and higher levels
of CX3CR1 in comparison to cDC1s [124]. Although a CD103+CD11b+ DC population exists in
the intestines [125,126], expression of CD11b and CD103 is mutually exclusive in skin dendritic
cells. In the mouse, both cDC1s and cDC2s require stimulation via Flt3 ligand (Flt3l) and CSF2 [127]
for development. For population maintenance, cDC1s require basic leucine zipper transcriptional
factor 3 (Batf3) and IRF8 [128,129], while cDC2s require IRF4 [129–131]. A subset of dendritic cells
expressing CD8α exists in lymphoid tissues but not in the skin [123,132]. These cells are capable of
cross-presentation, a process during which extracellular antigens, normally processed via the MHCII
pathway, are also presented via the MHCI pathway. Like CD8+ DCs, murine dermal cDC1s can
cross-present antigens [133,134].
In the mouse, cDC1s are associated with Th1 responses [135,136], while cDC2s are associated
with Th2 and Th17 [125,137–139]. Th1 responses are mainly specific for intracellular pathogens, while
Th2 and Th17 are for extracellular pathogens. Furthermore, both Th1 and Th17 cells are associated
with autoimmune disorders, while Th2 cells are associated with asthma and allergic disorders. Mice
deficient in Irf8, in which cDC1s are depleted, generate reduced numbers of Th1 cells in the skin in
response to cutaneous infection with herpes simplex virus (HSV) [135]. Kruppel-like factor 4 (Klf4)
has been shown to be required for maintaining conventional DC populations in the spleen [140].
Intriguingly, Tussiwand et al. demonstrated that expression of Klf4 in dDCs is critical for the induction
of Th2 responses in vivo [141].
dDCs are implicated in maintaining homeostatic interactions between the host and skin-resident
commensal bacteria. Naik et al. showed that mice deficient in Batf3 (necessary for cDC1) exhibit
reduced populations of CD8+ IL-17+ T cells specific for Staphylococcus epidermidis, suggesting that
cDC1s control the generation of commensal-specific T cells in the skin [52].
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Plasmacytoid DCs (pDCs) are a DC subset, found in the skin exclusively under inflammatory
conditions. pDCs are mass producers of IFNα, which is essential for viral defense [123]. In mice,
pDCs can be identified by the marker B220, which is also expressed by B lymphocytes [142–144].
In addition to their antiviral functions, pDCs have been implicated in autoimmune skin disorders such
as psoriasis [145]. Interestingly, a recent study showed that depletion of pDCs using CLEC4C-DTR
mice treated with bleomycin to induce skin fibrosis exhibited a decrease in dermal thickness and
collagen content when compared to WT control mice [142], suggesting that pDCs play a role in fibrosis.
Human dDCs are subdivided into cDC1 (CD141+), cDC2 (CD1c+), and CD14+ dDCs [123]. cDC1s
co-express CD304 (neuropilin-1), XCR1, and CD370 (CLEC9A). Unlike murine dDCs, human dDCs
do not express langerin [123,146]. Human cDC1s can cross-present in a similar manner to murine
cDC1s [147] and are potent in inducing Th1 responses [148]. cDC2s and CD14+ dDCs co-express CD11b
and CX3CR1. Interestingly, human cDC1s and cDC2s are both capable in inducing Th2 responses [148].
Human pDCs express CD304, CD303 and CD123 and like their murine counterparts are only found in
inflamed skin. Remarkably, a recent study showed that human peripheral blood pDCs upregulate the
expression of B cell maturation antigens upon activation via TLR9 signaling, suggesting that pDCs
play a role in the maintenance of plasma cells, in addition to their inflammatory functions [149].
Macrophages
Macrophages are found in the dermal layer of the skin and require IL-34 for survival [86,150].
Two sources of dermal macrophages have been identified so far. The first source is embryo-derived
progenitors that seed the skin prenatally and are self-renewing in a similar fashion to LCs [126].
The second and major source of dermal macrophages is circulating monocytes (monocyte-derived
macrophages) that mature once they reach the skin. This population replenishes roughly every
10 days [151,152]. Monocytes that give rise to dermal macrophages express lymphocyte antigen
6C (Ly6C), and home to the skin in a CCR2-dependent manner [129]. As monocytes mature into
skin-resident macrophages, the expression of CCR2 is downregulated [153]. CD64 expression is
prominent on dermal macrophages and is used as a marker to differentiate them from the dDCs [152,153].
CD36, DC-SIGN, and IL-10 are highly expressed by macrophages isolated from healthy skin, suggesting
that they adapt an immunoregulatory phenotype [153,154]. In steady state, macrophages remove
cellular debris [129,153], and have also been implicated in homeostatic hair regeneration [54,155].
Macrophages can be localized at post-capillary venules in the skin and secrete chemokines that drive
the recruitment of neutrophils [156]. However, the depletion of macrophages does not translate into
a reduction of neutrophils in the skin in wounds [152,157], indicating that dermal macrophages are
dispensable for neutrophil infiltration.
Macrophages are plastic, and one way to categorize their effector functions is as pro-inflammatory
“M1” or anti-inflammatory/pro-repair “M2.” It is important to note that bona fide M1 and M2
macrophages are generated only in vitro, and in vivo macrophages may simultaneously express M1
and M2 markers. Although investigators are beginning to shift away from the M1/M2 macrophage
paradigm [158], we will use this nomenclature to describe and categorize the functions of macrophages
as pro-inflammatory or anti-inflammatory/pro-repair. M1 macrophages express inducible nitric oxide
synthase (iNOS), and secrete inflammatory cytokines such as TNFα, IL-1β, and IL-6 [159,160]. M2,
or “alternatively activated” macrophages, adopt an anti-inflammatory and/or pro-repair phenotype.
M2 macrophages can be further subdivided into M2a, M2b, M2c, and M2d. M2a are known to be
pro-fibrotic due to TGFβ production [161]. M2b express the co-stimulatory molecule CD86 and as
such they are the most pro-inflammatory of the M2 subsets. M2c macrophages are induced by IL-10
or TGFβ, express the Mer tyrosine kinase (MerTK) and promote neovascularization [162], and have
high scavenging and debris clearing activity. M2d cells are responsive to IL-6 and exhibit a few of
the properties of tumor-associated macrophages such as secretion of IL-12 and IL-10 [162–165]. M2d
cells are also known to express high levels of the adenosine receptor A2AR in the presence of LPS [166].
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A2AR signaling has been shown to attenuate pro-inflammatory cytokine production [167], suggesting
that A2AR-expressing M2d cells may be involved in the resolution of the inflammatory response.
Mast Cells
Mast cells are commonly found in the dermal layer. Mast cells enter the skin from the bone marrow
as progenitors and mature locally in response to environmental cues [168]. While the exact progenitor
cell that gives rise to mast cells has been debated, common markers for committed mast cells progenitor
cells in the blood are recognized: Lin-c-Kit+ST2+CD34+CD16/32hiintegrinβ7hi [169]. Skin mast cell
maturation requires stem cell factor, derived from keratinocytes, while Th2-related cytokines such as
IL-3, IL-4, IL-9 and IL-10 induce and promote the proliferation of mast cells [170–172]. Mature mast
cells are FcεRI+c-Kit+CD16/32intintegrinβ7lo [173,174]. Intriguingly, the skin’s microbiome regulates
the population of mast cells in the skin. Germ-free mice contain fewer mature mast cells in the dermis,
and intradermal injection of these mice with staphylococcal-derived lipoteichoic acid induced the
expression of stem cell factor in keratinocytes, ultimately resulting in the rescue of the dermal mast cell
population [175].
In humans, mast cells are found in all areas of the skin but are most numerous in the arms and the
legs [176]. The density of mast cells in the papillary dermis increases with age and they are most often
localized in the proximity of PGP9.5+ nerve fibers expressing vasoactive intestinal peptide (VIP), which
was shown to suppress mast cell degranulation [177]. This has been associated with the reduction of
the amount of extracellular matrix remodeling in the skin observed during the later stages of life.
Mast cells contain granules containing preformed mediators such as histamine, sulfated
proteoglycans, serotonin, and tryptase and/or chymase. In both humans and mice, mast cells
resident in the skin express both tryptase and chymase, whereas other tissue-resident mast cells express
only tryptase [178].
Mast cells are classically known for their involvement in allergic reactions as they produce
and release copious amounts of histamine when their Fcε receptors are crosslinked via IgE-antigen
complexes [179,180]. They also make large amounts of prostaglandin D2 (PGD2), a lipid-derived
inflammatory mediator. The role of PGD2 is nebulous because it has been shown to exert both
pro-inflammatory and anti-inflammatory roles. PGD2 is well known to mediate inflammatory
responses in asthma [181,182]. However, PGD2 has also been shown to exert anti-inflammatory
functions in a murine acute lung injury model as mice that cannot produce PGD2 (H-PDGS−/−)
exhibited heightened vascular permeability and mRNA levels of pro-inflammatory cytokines in
comparison to WT control mice [183].
Mast cells are mass producers of leukotrienes (LTs), LTB4, LTC4, LTD4, and LTE4, with the latter
three consisting the cysteinyl leukotrienes (cysLTs). LTs are short-lived lipid inflammatory mediators
synthesized via the 5-lipoxygenase (5-LO) pathway. While a multitude of immune cell types express
the machinery to produce some of the LTs, mast cells and eosinophils produce the complete battery of
LTs. LTB4 has been shown to be effective in attracting neutrophils to sites of inflammation and cell
death [63] and is a potent inducer of mast cell degranulation [184]. However, excess LTB4 amounts in
the skin can lead to ineffective defense against Staphylococcus aureus infections in diabetic mice [185].
CysLTs are classically involved in allergic reactions such as rhinitis [186] and have been shown to
activate mast cells in an autocrine manner to induce expression of PGD2, mast cell protease-1 (MCP-1),
and histamine in mice and humans afflicted with aspirin-exacerbated respiratory disease [187].
A variety of cytokines and growth factors are produced by mast cells either constitutively or
in response to a stimulus [188]. Many of these cytokines and growth factors such as TNFα and
vascular endothelial growth factor (VEGF) may be preformed and packaged in mature mast cell
granules [189–191]. Proper formation of mast cell granules is mediated mostly by proteoglycan
serglycin [192].
Mast cell-derived IL-1β induces production of histamine and IL-8 in human mast cells, suggesting
that IL-1β is part of a positive feedback loop for mast cell activation [193,194]. TNFα produced by
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mast cells is known to drive migration of dermal dendritic cells to draining lymph nodes in a murine
model of hapten-induced contact hypersensitivity [195]. Interestingly, mast cell-derived TNFα is also
crucial for maintenance of tolerance toward allogeneic skin grafts in mice [196]. Furthermore, recent
studies revealed that mast cells are able to form immunological synapses with γδ T lymphocytes
when challenged with dengue virus [197] and can acquire MHCII expression via vesicle transfer from
dendritic cells after administration with dinitrofluorobenzene [198]. These studies suggest that dermal
mast cells can prime adaptive responses during cutaneous infections.
Eosinophils
Eosinophils are skin-resident cells [199,200], but not much is known about their role in tissue
homeostasis. Eosinophilic granules are loaded with potent and toxic proteins: major basic protein (MBP),
eosinophil peroxidase (EPO), eosinophil protein X/eosinophil-derived neurotoxin (EPX/EDN), and
eosinophil cationic protein (ECP) [61]. Human and murine eosinophilic granules also contain a variety of
preformed cytokines and chemokines released in response to appropriate stimuli [201–203]. The release
of their granular contents is mediated via a process known as piecemeal degranulation [204,205].
This process denotes degranulation in small portions so as to not jeopardize the viability of the cell.
Interestingly, cytokines can be chaperoned to secretory vesicles containing their cognate receptors,
thus allowing their rapid release from eosinophils [203]. Like mast cells, eosinophils produce all
types of LTs and PGD2 [206], with the latter being crucial for eosinophilic infiltration of the skin in
hypersensitivity reactions such as atopic dermatitis [207]. In addition, eosinophils generate extracellular
DNA traps (EET) containing eosinophil granules [208,209]. These traps are believed to play a role in
antibacterial defense.
Eosinophils are classically known to promote host defense against parasitic infections [210].
Interestingly, eosinophil-lineage deficient mice exhibit no difference in parasitic burden after
Schistosoma mansoni infection [211]. This seems to be site-specific and eosinophils seem to not
play a role in helminth clearance in intestinal sites [212]. However, eosinophils were shown to be
necessary in intestinal clearance of adult Heligmosomoides polygyrus [213]. Thus, there are still gaps in
our understanding of eosinophil-specific responses towards parasitic infections.
The roles of eosinophils in dermatoses, or skin diseases associated with eosinophilia such as
allergic contact dermatitis and urticaria, are well elucidated [61,214–216]. In eosinophilic dermatoses,
extensive eosinophilic degranulation in the skin results in local tissue damage.
Eosinophilic pustular folliculitis is an uncommon dermatosis hallmarked by the presence of
pruritic follicular papules and pustules associated with folliculotropic infiltration by eosinophils [217].
Skin lesions are most commonly found on the facial area and would typically last for one to two
weeks [61]. The recruitment of eosinophils by PGD2 [218] in eosinophilic disorders occurs by two
proposed mechanisms. First, by direct binding of PGD2 onto its cognate receptors on eosinophils,
thus inducing chemotaxis. Second, by inducing sebocytes to produce eotaxin-3 [219], which then
recruits eosinophils.
Eosinophilic cellulitis, also known as Wells’ Syndrome, is a rare disorder characterized by multiple
large, circular, and usually painful or pruritic edematous erythema [61]. While the cause of this
disorder is unclear, it has been well documented that the skin of patients with Wells’ Syndrome is
infiltrated by eosinophils along with aggregates of complexes comprised of collagen associated with
eosinophilic granular contents [220,221].
3.4.2. Lymphoid Immune Cells
The skin harbors different types of lymphoid cells (Table 1), all of which are important in both
steady state and inflammatory responses. Both human and murine skin contain γδ T lymphocytes and
αβ T lymphocytes, along with natural killer T cells. γδ T cells are the dominant T cell population in
murine skin, while αβ T cells are the dominant T cell population in human skin [222,223].
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αβ T Lymphocytes
In both mice and humans,αβT lymphocytes are found in the epidermis and dermis [224], and traffic
to the skin from the periphery via cutaneous lymphocyte antigen (CLA) interactions with E-selectin
(expressed on endothelial cells), which is upregulated under inflammatory conditions [225,226]. αβ T
lymphocytes in the skin are resident memory T cells (TRM), which are long-lived and distinct from
their circulating counterparts [227].
Most TRM in the skin are derived from antigen-specific effector T cells, which previously infiltrated
the tissue as a result of an infection. After resolution, these TRM cells seed all areas of the skin but are
denser in areas of antecedent infection [228]. Following a skin infection, TRM cells are also found in
distal organs such as the lung and gastrointestinal tract [228].
TRM express lower levels of CD28 than effector memory T cells, but can mount robust local
recall responses [227] without emigrating from the tissue to do so [229]. Interestingly, TRM also exert
sentinel-like functions by promoting recruitment of other memory T cells from the periphery to sites of
infection [230,231].
The most studied skin TRM are CD8+ T cells. Skin CD8+ TRM were shown to be effective against
HSV infections by inducing an IFNγ-mediated antiviral state in the tissue [230]. Additionally, CD8+
TRM cells were recently shown by the Gebhardt group to exert antitumor functions in a murine
transplantable melanoma model [232]. CD8+ TRM cells are usually found in the epidermis and may
dislocate dendritic epidermal T cells [233]. All CD8+ TRM express CD69, and a high proportion also
express CD103 [233]. CD103 is required for development of CD8+ TRM cells in the skin [233] and
mediates adhesion interactions with keratinocytes via an E-cadherin-independent manner [234].
CD4+ TRM cells also make up a significant portion of the skin-resident lymphocyte population
and are found in both the epidermis and dermis [233]. Although the function of CD4+ T cells in the
skin is not studied to the same extent as CD8+ TRM, they are often the dominant αβ T cell subset.
During steady state, clusters of antigen-presenting cells with CD4+ memory T cells are found around
the hair follicles in both murine and human skin, and cells in these clusters circulate between the skin
and periphery [67]. These clusters are formed because keratinocytes in the hair follicles produce IL-7
and IL-15, which are required for homeostatic maintenance of the T cell populations [235].
It is also well established that a proportion of skin CD4+ T cells are T regulatory cells (Tregs).
Crosstalk between LCs and Tregs has been shown to play a role in dampening immune responses in
contact hypersensitivities [236]. Tregs dysregulation leads to disorders such as pemphigus vulgaris,
alopecia areata, and systemic sclerosis [237,238].
Skin-infiltrating and -resident T cells play a role in the pathophysiology of various conditions such
as psoriasis, alopecia areata, and vitiligo, in which both CD4+ and CD8+ T cells are involved [239–242].
In psoriasis, infiltrating T lymphocytes produce IL-17, which is a central part of the disease’s
pathophysiology. The hair follicle bulbs and melanocytes are attacked by infiltrating cytotoxic CD8+ T
cells in alopecia areata and vitiligo, respectively. CD4+ TRM cells can promote the migration of dDCs
from the skin to draining lymph nodes in the context of autoimmune reactions [243].
Non-Conventional T Cells
The mechanisms by which T lymphocytes recognize peptide antigens complexed with the MHC
macromolecules are well delineated. However, T cells can also recognize free soluble antigens and
non-peptide antigens complexed with non-classical MHC-like molecules, and these T cells are termed
non-conventional. Here we will review the types of non-conventional T cells found in the skin:
γδ T Lymphocytes:
Unlike the αβ T lymphocytes, γδ T cells do not undergo the same stringent negative selection
process during development and are released from the thymus in waves, with the first wave of γδ T
cells seeding the dermis of the skin [244–246].
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Most γδ T cells in murine skin are found in the epidermis within the junctions between
keratinocytes, and are known as dendritic epidermal T cells (DETCs). Lymphocytes with DETC-like
characteristics have yet to be discovered in humans [222,223]. It was recently shown that DETCs are
derived from yolk sac progenitor cells and are self-renewing in the epidermis in a similar manner to
LCs [247]. DETCs express a canonical γδ T cell receptor and sample antigens via their dendrites, which
can extend from their mid cell body located in the apical epidermis to the border with the stratum
corneum, maintaining contact with local keratinocytes [248]. DETCs require keratinocyte-derived IL-7
for survival [249], and IL-15 is also important as DETCs were absent in IL-15−/− mice [250]. On the other
hand, DETC-derived IGF-1 and keratinocyte growth factor (KGF) promote keratinocyte proliferation
in steady state [251]. It is speculated that DETC-derived homeostatic factors are packaged in granules
and transported via the DETCs’ dendrites [252].
Once activated, DETCs retract their dendrites, adopt a round morphology, and secrete a range
of cytokines and growth factors. IL-17-producing DETCs are essential for inducing the expression
of β-defensins in the epidermis, thus playing a critical role in antimicrobial defense of the skin [253].
Interestingly, DETCs were shown to migrate to cutaneous draining lymph nodes in a CCR7-dependent
process after sensing stressed keratinocytes in an inducible Notch1 knockout mouse model, thus likely
playing a role in antitumor immunity [69].
γδ T cells found in the murine dermis express a Vγ4 chain and thus are distinct from their DETC
counterparts that express the Vγ5 chain [254]. Additionally, dermal γδ T lymphocytes require IL-7, but
not IL-15, for population maintenance [255], and are highly motile in comparison to DETCs that remain
in close contact with keratinocytes during tissue homeostasis [256]. The functions of dermal γδ T cells
in inflammatory skin conditions are well documented. This population of dermal T cells is inclined to
produce IL-17 [256], indicating their significance in cutaneous diseases such as psoriasis [257,258].
γδ T cells in the skin can also play a protective role in cutaneous defense, as a previous study
showed that γδ T cell-deficient mice exhibited larger lesions and reduced IL-17 production in response
to Staphylococcus aureus compared to WT control mice [70].
γδ T cells including DETCs are not MHC-restricted [259] and can recognize soluble
antigens [259,260], antigens derived from damaged or stressed cells [261–263], or antigens complexed
with non-classical MHC molecules such as CD1b, CD1c, and CD1d [264,265] or MHCI-related chain
A/B (MICA/MICB) [266]. A recent study suggests that γδ T cells also recognize Btnl proteins, which
are part of the B7 superfamily [267].
Other CD1-Restricted Cells
CD1 molecules are essential for presenting lipids antigens to T cells and are categorized under
group I (CD1a, CD1b, CD1c) or group II (CD1d and CD1e) [268,269]. In addition to γδ T cells, some
αβ T cells and natural killer T cells are CD1 restricted.
Humans contain both group I and group II CD1-restricted T cells, while mice only contain group
II CD1-restricted T cells. LCs express CD1a, which was recently shown to regulate Th17-mediated
inflammatory responses in the skin [270]. Autoreactive T lymphocytes specific to squalene, wax esters,
and triglycerides home to the skin, and these lipids are presented by CD1a [271]. CD1b molecules
present a diverse array of mycobacterial lipids such as mycolic acid, glucose monomycolate, and
phosphatidyl mannosides [272–275]. CD1c molecules have been shown to present self-lipid antigens
such as methyl-lipophosphotidic acid, which is known to aggregate in leukemic cells [276]. A previous
study showed that mice containing autoreactive CD1c-restricted T cells were efficient in eliminating
human leukemic cells, suggesting that these autoreactive CD1c-restricted T cells play a role in tumor
immunity [276]. Unlike the TRM lymphocytes, CD1-restricted T cells have not been documented to be
present in healthy skin, but are readily found in the context of inflammatory conditions. Both CD1b
and CD1d have been documented in human cutaneous Borrelia burgdorferi infections [277]. Group I
CD1-restricted T lymphocytes elicit IgE responses when presented with phospholipid antigens derived
from cyprus pollens, suggesting that they contribute to pollen hypersensitivities [278]. CD1a expressed
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on LCs is central on skin inflammatory conditions such as atopic eczema [270,279] and psoriasis [280].
Furthermore, group I CD1-restricted T cells have been implicated to play a role in controlling the
microbiota inhabiting the skin. Group I CD1-restricted T cells have also been well documented in the
defense against Mycobacterium tuberculosis [281,282].
Group II CD1d-restricted T lymphocytes have been more extensively studied in mice. CD1d is
expressed by keratinocytes and dermal dendritic cells [283]. Most group II CD1d-restricted T cells
are also known as invariant natural killer T cells (iNKT). iNKT cells are involved in hypersensitivity
reactions as they produce IL-4 in response to haptens in the skin, leading to sensitized iNKT cell
accumulation [284]. Similar to the group I CD1-restricted T cells, iNKT cells also exhibit antitumor
activity [285]. Interestingly, it has also been suggested that iNKT cells play a role in suppressing
autoimmune responses in the skin, as a deficiency of CD1d resulted in increased numbers of skin lesions
in a MRL-lpr/lpr murine model of systemic lupus erythematosus [286]. Furthermore, small non-lipid
synthetic molecules can activate T cells via CD1d presentation [287]. CD1e molecules are expressed in
the Golgi compartments of immature DCs and are later localized in the lysosomes of mature DCs [288].
CD1e is known to be crucial for the antigen processing of bacterial glycolipids to CD1b-restricted T
cells [289]. However, not much is known about the roles of CD1e in cutaneous inflammation.
B Lymphocytes
B cells are rather sparse in the skin in steady state and it is unclear whether they are indeed
resident to the skin [290–292]. However, the roles of B lymphocytes in skin inflammatory conditions
are well documented. In humans, B cells are found in elevated levels in cutaneous diseases such as
atopic eczema, cutaneous leishmaniasis, and cutaneous sclerosis [293–295]. B cells are found in the
reticular dermis over the course of these diseases and are associated with increased levels of IgM, IgE,
and IgG. In a similar manner to T lymphocytes, B lymphocytes traffic to the skin tissue via CLA [296].
It has been suggested that the CCL20-CCR6 axis is important in addition to CLA for B cell homing
from lymph to the skin [291,297]. A population of B-1-like cells is found in inflamed skin in both
humans and mice and migrates from the peritoneum via integrin α4β1 [298]. B cells also play a role in
delayed-type hypersensitivity reactions in the skin. Peripheral B-1 cells produce allergen-specific IgM
antibodies as soon as day one post-induction with either ovalbumin or keyhole limpet hemocyanin.
This leads to the formation of immune complexes between the IgM antibodies and allergens and
activation of the complement cascade mechanisms, ultimately resulting in recruitment of T cells to
the affected skin site [299,300]. Autoimmune bullous diseases are characterized by the presence of
autoantibodies that are reactive to structural proteins of the epidermis [301]. Pemphigus vulgaris is
such an example in which desmoglein-3 autoantibodies lead to the formation of blisters in the skin [302].
Intriguingly, a population of regulatory B cells (Bregs) have been suggested to play suppressive roles in
certain cutaneous inflammatory conditions. Bregs exert their immunosuppressive functions through
the production of large amounts of the regulatory cytokine IL-10 [303]. In an imiquimod-induced
murine psoriasis model, mice that lacked most B cells (CD19−/−) exhibited more severe symptoms
when compared to their WT counterparts. Adoptive transfer of WT B cells to the CD19−/− mice
ameliorated psoriasis symptoms, suggesting that a population within these B cells play a therapeutic
role in alleviating the disorder [304].
3.4.3. Non-Immune Cells
Pattern recognition receptors (PRR) are expressed by most cells of the skin and have been
characterized on keratinocytes, fibroblasts, adipocytes, melanocytes, and endothelial cells [305].
Activation of these receptors results in the production of cytokines and chemokines by non-immune
skin cells, thus participating in the local immune response [306–309].
Keratinocyte-derived inflammatory responses have been extensively studied. These cells express
almost all intracellular and extracellular PRRs and produce a variety of cytokines, chemokine and AMPs
to protect the host against infection [78–80]. As mentioned earlier, keratinocytes both in the epidermis
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and skin elements are in constant interaction with local immune cells and produce factors crucial
in homeostasis and in tissue repair [85,235,248,249]. Other studies demonstrated that keratinocytes
produce IL-33 in response to hypoosmotic stress [76], and that human and murine keratinocytes
produce IL-6 and IL-1βmediated by NFκB signaling in response to UVB irradiation [310]. Evidence
has also shown that keratinocytes can produce inflammatory cytokines and chemokines mediated by
STAT3 signaling in the presence of IL-25 in a murine psoriasis model, suggesting that keratinocytes play
a crucial role in the pathophysiology of the disease [311]. Additionally, keratinocytes have mechanisms
in place to control overactivation of inflammatory responses [312].
Fibroblasts immunomodulatory functions have also been well delineated. They express PRRs,
synthesize many cytokines, and were shown to produce AMPs [313]. Dermal fibroblasts and
keratinocytes produce serum amyloid A in response to PRR signaling [77], which is believed to induce
the production of pro-inflammatory cytokines from various immune cells [314]. A recent investigation
showed that human fibroblasts cultured in vitro produced massive amounts of TNFα, IL-1β, IL-6, IL-8,
and IL-25 when subjected to thermal stress [315].
4. Innervation of the Skin
The skin is highly innervated by sensory nerves expressing receptors that can sense pain (nociceptors),
itch (pruriceptors), temperature (thermoreceptors), and touch (low-threshold mechanoreceptors;
LTMRs) [316]. Nociceptors, pruriceptors, thermoreceptors, and some mechanoreceptors are present
as nerve free endings. Other mechanoreceptors are present in the skin as corpuscles. The cell
bodies of nerves that innervate the skin are located in the trigeminal and dorsal root ganglia [1].
Nociceptive nerves are in close contact with hair follicles and epithelial cells with their free nerve
endings terminating at various levels of the epidermis [317]. Merkel cells are oval-shaped cells involved
in mechanosensation (light touch) interspersed in the basal layer of the epidermis and innervated
with sensory fibers. Merkel cells are anchored to the epidermis through cytoplasmic protrusions
from the Merkel cell to keratinocytes and by desmosomes [316]. Other mechanoreceptors in the
skin are Meissner’s and Pacinian corpuscles. Meissner’s corpuscles are localized in the papillary
dermis and are sensitive to touch, while Pacinian corpuscles are located in the reticular dermis and
are responsive to pressure and vibration [318,319]. Both types of corpuscles are supplied by Aα and
Aβ sensory nerve fibers that are situated in the sensory ganglia [319]. Thermoreceptors, critical for
sensing thermal differences between the skin and the external environment, are expressed on both heat-
and cold-sensitive nerves, with the skin being more densely populated by cold-sensitive nerves [320].
Activation of thermally sensitive nerves to either heat or cold results in vasodilation, vasoconstriction,
sweating, or shivering [321].
Noxious stimuli are detected by nociceptors, which have been shown to orchestrate local
immune responses. The transient receptor potential (TRP) ligated-ion channels are critical detectors of
pain-inducing stimuli. Members of the TRP family function as both thermoreceptors and nociceptors.
TRPA1 respond to cold stimuli whereas TRPV1 and TRPV2 respond to hot stimuli [322]. Activation of
the TRP channels involves an influx of Ca2+ and Na+ ions through the channel pore, which subsequently
leads to neuronal plasma membrane depolarization and opening of the Nav/Cav channels to prime
action potential firing of the neuron [323].
TRPA1 and TRPV1 also function in pruritus of the skin and control the function of dermal
macrophages [324,325]. Activated TRP nociceptors can release calcitonin gene-related peptide (CGRP),
which has been shown to modulate immune responses. CGRP has been shown to promote the
migration of T cells to inflamed sites by inducing adhesion of T cells to fibronectin, a component
of the extracellular matrix [326]. However, CGRP can inhibit macrophage-mediated activation of
T cells [327], indicating that CGRP exerts immunoregulatory functions. CGRP also affects immune
responses exerted by neutrophils, as Pinho-Ribeiro et al. demonstrated that CGRP inhibits neutrophilic
killing of Streptococcus pyogenes in a murine model of necrotizing fasciitis [328].
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TRPV1 has also been implicated in cutaneous disorders. TRPV1 ablation attenuated skin
inflammation in a murine model of psoriasis [329]. A recent study showed that histamine increases
the sensitivity of TRPV1 in mouse dorsal root ganglia neurons, in vitro [330,331]. There are four
known histamine receptors: HR1-HR4, and three of these receptors are expressed on the dorsal root
ganglia [332], implicating that activation of these receptors is integral in nociception [333]. Thymic
stromal lymphopoietin (TSLP) is a protein produced by epithelial cells and promotes the expansion of
lymphocytes and Th2 cells via DC activation [334]. Dendritic cells themselves can also produce copious
amounts of TSLP in response to ligation of β-glucans to the receptor Dectin-1 [335]. Interestingly,
TSLP has also been shown to activate skin nociceptive sensory nerves and is highly associated with
pruritus [336].
Remarkably, immune cells in the skin can regulate the innervation of the tissue. A previous study
demonstrated that depletion of langerin+ cells in langerin-DTR mice via diphtheria toxin treatment
exhibited a significant reduction in the numbers of PGP9.5- and CGRP-expressing nerves, and a
decrease in the levels of nerve growth factor (NGF) and glial-cell-line-derived neurotrophic growth
factor (GDNF) [337]. Furthermore, TNF-producing mast cells induce growth of nerve fibers in mice
when subjected to oxazolone-induced contact hypersensitivity [338].
5. Skin Microbiome
Commensal microorganisms including bacteria, fungi, and viruses are found in the epidermis,
dermis, and dermal appendages, and constitute an additional layer of defense for the host. Their
communities are fairly stable over time but are site- and individual-specific [339]. The microbiome
colonizes the skin early after birth in an immune-regulated process [340]. By occupying accessible areas,
the microbiome regulates colonization of the tissue by pathogenic microorganisms [341], promotes
homeostatic immunity [342] and modulates gene expression [343].
The major commensal microbes inhabiting the skin are Staphylococcus epidermidis (S. epidermidis)
and Propionibacterium acnes (P. acnes) [341]. Commensals also protect the host by competing for
habitable space, thus preventing colonization of the skin by pathogenic microbes. Colonization of the
skin by pathogenic strains is usually associated with low presence of commensal stains [344]. Some
of these commensal strains can secrete their own antimicrobial agents, such as bacteriocins, which
inhibit the growth of pathogenic bacterial strains [345]. The Gallo group found that coagulase-negative
S. epidermidis on human skin produces its own AMPs that are protective against the pathogenic
Staphylococus aureus (S. aureus) colonization [346]. Commensals can also indirectly inhibit the growth
of pathogenic strains. P. acnes in wounded mice fermented glycerol into short-chain fatty acids, that
inhibited the colonization of the wound by the pathogenic methicillin-resistant S. aureus (MRSA)
likely through a process that resulted in lowering the intracellular pH of MRSA [347]. Furthermore,
commensal S. aureus protects against pathogenic MRSA by inducing antibody production against
α-hemolysin [348].
Commensal bacteria can manipulate the host’s immune response. Cogen et al. showed that
S. epidermidis secretes delta toxin, which can induce the formation of neutrophil extracellular traps and
promote AMP activity against group A Streptococcus [349]. Lipoteichoic acid derived from commensal
S. epidermidis recruited mast cells to the skin via TLR2 signaling when challenged with vaccinia
virus [350]. Remarkably, the same lipoteichoic acid produced from S. epidermidis can ameliorate
tissue pathology in mice exposed to poly I:C via TLR2-mediated inhibition of TLR3, suggesting that
commensals can reduce tissue damage after an injury by suppressing inflammation [351]. Linehan et al.
recently found that S. epidermidis antigens are presented to CD8+ T lymphocytes, and that these
lymphocytes are capable of producing IL-17 (Tc17) or IFNγ (Tc1) [352]. The S. epidermidis-responsive
Tc17 and Tc1 populations were also shown to be restricted to the non-classical antigen presenting
molecule MHCIb. Commensal bacteria occupying hair follicles may be responsible for the clustering of
memory T lymphocytes to the vicinity. It is thought that these resident bacteria induce the production
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of chemokines and cytokines by hair follicle keratinocytes, thus promoting the recruitment of immune
cells [235,353].
Surprisingly, commensals may play a role in promoting antitumor immunity. Nakatsuji et al.
demonstrated that the S. epidermidis produce 6-N-hydroxyaminopurine (6-HAP), which suppresses
melanoma growth in C57BL/6 mice, and protects against UV-induced neoplasia in SKH-1 hairless
mice [354]. The same study also found that 6-HAP is produced by S. epidermidis inhabiting human skin.
The fungi kingdom in the skin is not very diverse and the most commonly found species is
Malassezia spp. [355,356]. Malassezia cannot synthesize its own lipids and therefore is mostly found
on sebaceous skin, where it can convert the skin’s endogenous lipids into free fatty acids, suggesting
that Malassezia contributes to cutaneous defense [357]. However, Malassezia may also be involved in
promoting skin pathologies. A recent study showed that most patients with atopic dermatitis exhibit
some degree of sensitization to Malassezia antigens [358]. Furthermore, Malassezia has been implicated
to play a role in causing dandruff and seborrheic dermatitis via endogenous lipase activity [359].
Viruses also reside in healthy skin. The viral microbiome (virome) is not well delineated and
although not as diverse as the bacterial kingdom, it exhibits more diversity than that of fungi [360].
In humans, one of the common viruses found in the skin is the Merkel cell polyomavirus (MCV),
which is found in about 60% of adults [361]. Two other polyomaviruses have been found on human
skin: human polyomaviruses-6 and 7 (HPyV6 and HPvV7) [362]. While not much is known about
the functions these commensal viruses exert on healthy skin, individuals with compromised immune
responses can be afflicted with tumors such as Merkel cell carcinoma that are associated with the
polyomaviruses [363].
6. Skin Immune Responses in Wound Healing
The wound healing process consists of four tightly orchestrated and largely overlapping phases:
hemostasis, inflammation, proliferation, and remodeling (Figure 1).
In hemostasis, the skin tissue isolates the injured area from the environment and prevents
further bleeding by forming a clot. In the case of an insult, tissue factor (TF), normally located in the
subendothelial spaces of the skin, is exposed to blood via compromised vasculature. This initiates the
coagulation cascade, during which platelets adhere to components of extracellular matrix constituents,
secrete their granular contents, and aggregate [364,365]. Platelets release granular contents that consist
of coagulation factors IV, V, and VIII, platelet-derived growth factor (PDGF), calcium, serotonin,
histamine, and epinephrine. Collectively, these granular contents all play a role in further platelet
activation and aggregation, which seals off the injured area. At the same time, zymogen forms of
plasminogen and thrombin are converted into functional enzymes [366]. The wound clot consists of
fibrin and serves as a scaffold for keratinocytes to begin re-epithelialization and for immune cells to
infiltrate the wound area [7,81,366,367].
The inflammatory phase is characterized by infiltration of the wound by immune cells, such as
neutrophils, monocytes, and lymphocytes. The milieu of the wound during this phase consists of high
levels of pro-inflammatory mediators, which serve to recruit other immune cells from the periphery.
The purpose of the inflammatory phase is for the host to ward off any pathogens that have entered the
wound site and prevent infections. In addition, phagocytes clear out necrotic debris.
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Figure 1. Schematic of normal and impaired wound healing. The inflammatory phase is hallmarked 
by infiltration of the wound by activated immune cells. Chemotaxis of immune cells to the injury site 
is facilitated by the presence of inflammatory mediators, which can be produced by skin-resident cells 
such as keratinocytes, dermal dendritic cells, Langerhans cells, and macrophages. The proliferative 
phase is characterized by expansion of keratinocytes and endothelial cells to restore the barrier 
function of the skin and vasculature of the tissue, respectively. Fibroblasts are major producers of 
collagen fibers in the wound bed and a source of de novo synthesized extracellular matrix. Efficient 
wound healing is characterized by the timely transition from the inflammatory to the proliferative 
phase. For this to occur, several events have to happen in concert: neutrophil numbers in the wound 
decrease, macrophages shift in phenotype from inflammatory to reparative, collagen deposition, and 
revascularization, thus facilitating wound closure. Chronic wounds are characterized by high levels 
of inflammation, and decreased production of growth factors, decreased proliferation of endothelial 
cells, and lack of re-epithelialization. For simplicity, the remodeling phase, certain immune cell types 
such as tissue-resident T lymphocytes, and nerve fibers are omitted. Wound complications such as 
bacterial infections and scarring are also omitted.  
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The inflammatory phase is characterized by infiltration of the wound by immune cells, such as 
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high levels of pro-inflammatory mediators, which serve to recruit other immune cells from the 
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The proliferative phase is marked by expansion of skin-resident cells including keratinocytes, 
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restore the barrier function of the epidermis. Granulation tissue, a matrix of immune cells, fibroblasts, 
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Figure 1. Schematic of normal and impaired wound healing. The inflammatory phase is hallmarked
by infiltration of the wound by activated immune cells. Chemotaxis of immune cells to the injury site is
facilitated by the presence of inflammatory ediators, w ich can be produced by skin-resident cells
such as keratinocytes, dermal dendritic cells, Langerhans cells, d macrophages. The proliferative
phase is ch racterized by expansion of keratinocytes and endothelial cells to restore the barrier
function of the skin and vasculature of the tissue, respectively. Fibroblasts are major producers of
collagen fibers in the wound bed and a source of de novo synthesized extracellular matrix. Efficient
wound healing is characterized by the timely transition from the inflammatory to the proliferative
phase. For this to occur, several events have to happen in concert: neutrophil numbers in the wound
decrease, macrophages shift in phenotype from inflammatory to reparative, collagen deposition, and
revascularization, thus facilitating wound closure. Chronic wounds are characterized by high levels of
inflammation, and decreased production of growth factors, decreased proliferation of endothelial cells,
and lack of re-epithelialization. For simplicity, the remodeling phase, certain immune cell types such as
tissue-resident T lymphocytes, and nerve fibers are omitted. Wound complications such as bacterial
infections and scarring are also omitted.
The proliferative phase is marked by expansion of skin-resident cells including keratinocytes,
fibroblasts, and endothelial cells [368]. During this phase, keratinocytes expand and migrate to
restore the barrier function of the epidermis. Granulation tissue, a matrix of immune cells, fibroblasts,
and de novo generated blood vessels, begins to form and replaces the fibrin clot, which forms the
substrate for migrating keratinocytes to adhere to. Blood that was matrixed with the fibrin clot forms
a scab, which serves as an outer shield for the underlying migrating keratinocytes [81]. Fibroblasts
differentiate into myofibroblasts, which are responsible for providing contractile forces in wound
closure [369]. The Horsley group showed that IL-22 promotes fibroblast activity during wound healing
by inducing collagen deposition in murine wounds [370]. Remarkably, it was recently discovered by
Guerrero-Juarez et al. through single cell mRNA-seq analyses that fibroblast populations in the wound
are heterogenous and consist of up to 12 different subsets [55], with some of these subpopulations being
localized in different areas of the dermis. Both fibroblasts and myofibroblast begin producing a collagen
network consisting of immature type III fibers that act as the foundation of the new extracellular
matrix [7,81].
In the remodeling phase, the injured tissue attempts to restore its original architecture. Many
immune cells, endothelial cells, and myofibroblasts undergo apoptosis or are removed from the wound,
leaving mostly the newly developed extracellular matrix and collagen fibers. Macrophages that remain
in the wound at this phase produce and secrete matrix metalloproteases (MMPs) that are involved
in the remodeling of the extracellular matrix by removing any excess collagen [81]. The removal of
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excess collagen by MMPs also serves to reduce any scar tissue that forms after injury. Furthermore,
the newly synthesized immature collagen type III fibers from the proliferative phase begin maturing
into the terminal collagen type I conformation [371]. During this phase, LCs begin to repopulate
the neo-epidermis [51,372]. Once initiated, the remodeling phase can continue for at least one year
post-injury [81,366].
The immune response is central during the entirety of the wound healing process (Table 1).
Shortly after the injury, neutrophils, the first cells to arrive at the wound, are crucial for defense again
pathogenic microbial colonization of the wound. During inflammatory responses, neutrophils release
neutrophil extracellular traps (NETs) in a process called NETosis, which assist in the immobilization of
pathogens. The magnitude of NETosis determines whether the process results in death or viability of
neutrophils [373]. NETs are complexes containing histones, granular enzymes and peptides including
neutrophil elastase, defensins, and cathelicidins [373,374]. Recently, it was discovered that neutrophils
produce and secrete coagulation factor XII, which can be used to induce NETosis in an autocrine
manner, and can recruit other neutrophils from the periphery [62]. Neutrophils can further amplify the
inflammatory immune response by secreting potent chemoattractants such as IL-8 and LTB4, which
recruit other neutrophils to the injury site [63,375]. In addition to their inflammatory roles, neutrophils
secrete factors that promote healing, such as laminin 5 β-3, which allows keratinocytes to adhere to the
dermal layer of the wound bed [64]. Intriguingly, a small subset of neutrophils has been identified to be
pro-angiogenic and is responsive to VEGF-A in both humans and mice [65,66]. These pro-angiogenic
neutrophils may be categorized under a unique phenotype, coined as “N2”, in a similar manner
to the M1 and M2 macrophages, by Fridlender et al. during an investigation of tumor-associated
neutrophils [376].
Interestingly, catecholamines have been documented to play a role in the neutrophilic response
during wound healing. The Isseroff group showed that wounded mice that were treated with
epinephrine exhibited significant increases in the neutrophil population in the wound site, suggesting
that catecholamines mediate trafficking of neutrophils to injury sites [377]. Blockade of catecholamine
signaling decreased the local neutrophil population [377] and promoted wound healing [378,379].
Monocytes from the periphery infiltrate the wounded tissue shortly after neutrophils. Depending
on the environmental milieu, monocytes can give rise to M1 or M2 macrophages, or dendritic cells once
they arrive at the site of inflammation [150]. Recently, the Gurtner and Plikus groups demonstrated that
wound-infiltrating F4/80+ monocytes can give rise to new fibroblasts, suggesting that monocytes are a
source of de novo fibroblasts in injured skin [55,380]. Macrophage subsets exert multiple functions such
as clearance of invading pathogens, secretion of growth factors that can stimulate revascularization
and tissue repair, and expression of metalloproteases that are involved in restoration of the tissue
architecture [368,381,382]. M2 macrophages produce VEGF, which promotes angiogenesis [163,383],
promote fibroblast proliferation and secrete TGFβ and PDGFβ, which collectively lead to accelerated
tissue repair [381]. In addition, macrophages in the wound bed secrete cytokines and growth factors
that drive the proliferation and activation of a population of myofibroblasts that express similar markers
to those of adipocyte progenitor cells [56], which are known to be critical for wound healing [384].
Interestingly, depletion of macrophages has been associated with impaired healing [157,385,386], and
this reparative effect is likely exerted later in the wound healing process, concomitant with their
switch towards M2 function [387]. It is not quite clear what exactly causes the switch of macrophages
towards an M2-like (pro-reparative) phenotype. Previous studies demonstrated that phagocytosis
of apoptotic cells, such as neutrophils [388,389], by macrophages induces signals that initiate the
resolution of inflammation, a process known as katabasis, and the return of the tissue to homeostatic
functions [388,390,391]. In support of this, a recent study in a murine myocardial infarction model
showed that mice depleted of neutrophils exhibited a reduction in the MerTK+ M2c macrophages,
which are involved in clearing of apoptotic cells and debris [392]. However, studies have shown that
neutrophils do not always undergo apoptosis at the wound site and have been documented to exit the
wound area and migrate via the lungs to the bone marrow, where they are eliminated [393].
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LCs begin to repopulate the neo-epidermis during the remodeling phase of healing [51,372], and
a study in humans showed that patients who exhibit efficient healing contained higher densities of
LCs in the skin [394]. The source of de novo LCs in healing tissue can be either the local pre-existing
LC population in unwounded tissue or from blood-circulating monocytes [395]. In mice, stressed
keratinocytes upregulate ligands for lymphocyte activation receptor natural killer group 2D (NKG2D),
such as Rae-1, which leads to the migration of LCs from the epidermis [51,396]. Interestingly, mice that
do not express NKG2D ligands (Klrk1−/−) exhibit a delay in wound healing, suggesting that crosstalk
between keratinocytes and LCs is important for efficient wound healing [397].
Expansion of dendritic cells in the skin enhances healing by promoting re-epithelialization,
angiogenesis, granulation tissue formation, growth factor production [53], and promotes skin wound
healing via the MiR-21/PTEN signaling axis [398]. pDCs infiltrate the wound bed during the
inflammatory phase and secrete IFNα/β [143]. It was shown that antibody-mediated depletion of
pDCs in murine wounds results in a decrease of the inflammatory response, but also a reduction in
wound closure [143].
Lymphocytes also play a crucial role in wound healing. In mice, DETCs have been shown to be
associated with wound healing as they can affect keratinocyte proliferation and epidermal thickening
by secreting KGF [72]. Human Vδ1-expressing γδ T cells are activated after injury and secrete IGF-1,
which promotes the healing process [399]. A previous study by the DiPietro group showed that CD4+
and CD8+ T lymphocytes can influence the wound milieu by regulating the mRNA expression of
various cytokines and growth factors, but does not significantly affect wound closure [400]. Regulatory
T cells have been implicated in wound inflammation as a study demonstrated that depletion of Tregs
using a FoxP3-DTR murine wound model resulted in increased inflammatory population of Ly6C+
monocytes in the wound, leading to impaired healing [401]. Tregs also play a role in the maturation of
newly formed vasculature as depletion of Tregs in mice resulted in a decrease in the numbers of mature
endothelial cells associated with myofibroblasts after excision injury [68].
iNKT cells have recently been documented to play a role in wound healing as iNKT-deficient
mice (Jα18KO) exhibited an increase in neutrophilic inflammation of the wound, resulting in delayed
healing when compared to WT mice [73].
MicroRNAs (miRNAs) are RNA sequences of approximately 22-23 nucleotides and have been
studied extensively in the past. The roles of miRNAs in cutaneous wound healing are now becoming
more understood and appreciated. The most studied miRNA in wound healing is miR-21, which is
highly expressed in keratinocytes and fibroblasts. It has been shown that inhibition of miR-21 results
in impaired healing in mice [402]; however, blockade of this miRNA in humans has the opposite
effect [403]. Other miRNAs of interest in wound healing are miR-29 [404] and miR-210 [405], and
further research is needed to fully elucidate the roles of these miRNAs in wound healing.
The skin maintains a net negative charge relative to the tissue laying underneath it. In the case of
an injury, ion leakage occurs, creating a voltage gradient throughout the wound site [406]. The application
of a voltage gradient in the wound activates signaling molecules that are critical for wound healing
such as integrins, epidermal growth factor receptors, and phosphoinositide 3 kinases [407,408].
The migration of cells by endogenous bioelectrical cues, known as galvanotaxis or electrotaxis, can
occur at the site of injury [409]. Many cells are responsive to electrical fields, including epithelial
cells, fibroblasts, lymphocytes, macrophages, endothelial cells, and neuronal cells [406], although
these cells migrate in different manners. For instance, stromal fibroblasts migrate toward the anode
whereas epithelial cells migrate toward the cathode [410,411]. A recent study by Nakajima et al.
showed that galvanotaxis/electrotaxis of human corneal epithelial cells is largely influenced by the
purinergic receptors P2X and P2Y [412]. Electrical fields may also play a role in the migration of
stem cells, which are crucial for efficient wound healing. A previous in vitro study showed that
murine adipose-derived stem cells are responsive to electrical currents and their migratory speed is
increased proportionally to the strength of the applied electric field [413], suggesting the potential use of
electrotherapy in promoting migration of stem cells to injury sites. Interestingly, a recent in vivo study
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showed that wounded mice that were treated with a bioelectric plaster exhibited accelerated healing,
which was, however, associated with a thickened epidermis in comparison to mice that received no
treatment [414]. Previous clinical studies have assessed the efficacy of various electrotherapies (direct
current, pulsed current) in accelerating the healing of lower extremity wounds [415]. One such study
reported that venous leg wounds treated with a low direct current for six weeks resulted in enhanced
healing [416]. A more recent study showed that treatment of pressure ulcers with pulsed current
electrotherapy in supplementation with standard wound care significantly increased wound healing in
elderly patients [417].
Ageing skin exhibits changes in its intrinsic properties and reduced ability to restore itself after an
injury. Some of these changes include decreases in barrier function, dermal thickness and fibroblast
numbers, tissue microvasculature density, and insulation ability [418]. Keyes et al. showed that
epidermal cells proliferate at a slower rate in aged mice after injury, and that aged keratinocytes were
slower at re-epithelialization in scratch wound assays [419].
6.1. Impaired Healing
Disruptions in any of the phases of wound healing result in impaired healing. A prolonged
inflammatory phase may result in chronic wounds and inefficient wound healing [420] (Figure 1).
Perturbed proliferative and remodeling phases may lead to irregular wound closure, fibrosis, and
scarring [81]. Moreover, some chronic wounds express elevated levels of MMPs, which can impair
the formation and compromise the structural integrity of the fibrin clot [421–423]. Impaired healing
results in increased hospitalization time, higher costs, and lower quality of life. Venous stasis ulcers,
arterial stasis ulcers, pressure ulcers and diabetic wounds are the most common non-healing chronic
wounds. Venous stasis ulcers are associated with tissue inflammation and iron overload [424], which
is suggested to impair M1 macrophage transition to M2 [425]. Additionally, the cytokine environment
may impair fibroblast function [424,425]. Arterial leg ulcers occur as a result of reduced arterial blood
flow and subsequent tissue perfusion. Also, pressure ulcers are observed in patients with low mobility
due to tissue necrosis and capillary damage [426–428]. In this section, we will focus on diabetic wounds
in which immune deregulations have been extensively studied. In addition, we will discuss burns, an
inflammatory type of wound usually associated with deregulated healing.
6.1.1. Diabetic Wounds
Diabetic patients suffer by complications such as neuropathies, vascular diseases due to poor
blood circulation, and perturbed immune responses leading to opportunistic infections [429]. The most
common wound in diabetic patients are those that affect the feet. Diabetic foot wounds may not
be detected due to concomitant neuropathies, which reduce the patients’ nociception. As a result
of neglect, compounded by complications of diabetes, the initial wound in the foot becomes a
slow-healing ulcer [430,431]. In extreme cases, significantly delayed healing may lead to amputation
of the affected extremity. The skin of diabetic patients exhibits disruptions in mechanisms that
are central to maintaining homeostasis and structural integrity. Diabetic skin is associated with
reduced VEGF expression [432] and recruitment of smooth muscle cells [433], implicating that the
vasculature of the tissue is perturbed. Studies in diabetic mouse models showed that hyperglycemia
disrupts the barrier function of the skin, reduces epidermal proliferation, and decreases homing
of endothelial progenitor cells from the bone marrow to the skin [434,435]. TF levels in diabetic
skin are decreased in comparison to normal skin, implying that the coagulation cascade that occurs
immediately after wounding is dampened [436]. Topical application of TF on wounds of diabetic
mice seems to improve healing, although it does not improve healing to the same efficiency as that of
non-diabetic wounds [436]. Proliferation and migration of keratinocytes in diabetic skin are dampened
in high-glucose environments [437,438], indicating that wound closure is decelerated in diabetic skin.
In both diabetic mice and patients, wounds contain neutrophils that undergo excessive NETosis,
usually leading to collateral tissue damage [374,439]. Interestingly, macrophages in diabetic wounds
Int. J. Mol. Sci. 2019, 20, 1811 21 of 53
are dysfunctional, which results in inefficient neutrophil clearance [440], chronic inflammation [441],
and impaired growth factor production [442], and consequently inefficient healing. Importantly,
transfer of bone-marrow-derived M2 polarized macrophages were shown to improve healing in mice
that were hyperglycemic due to hyperplastic beta cells [443]. Inflammatory lipid mediators such as
leukotrienes are also found in diabetic wounds and it is speculated that they prolong inflammation,
thus impairing wound healing [185,444]. Higher numbers of mast cells have been observed in the skin
of diabetic patients in comparison to non-diabetics [445], and prevention of mast cell degranulation by
disodium cromoglycate treatment accelerated healing in diabetic mice when compared to untreated
diabetic mice [445].
The current standard of care for slow-healing wounds is to debride the injury site. This is done in
an attempt to reveal viable tissue and to provide space for the tissue to proliferate and expand [446].
Sometimes a moist dressing is used on the injury site in an effort to support the inflammatory phase
of wound healing and re-epithelialization of the wound [447]. In addition, acellular and cell-loaded
matrices are used in many cases of chronic wounds with varying degrees of success [448].
A variety of mechanisms that accelerate healing in diabetic wounds have been identified over the
years. VEGF accelerates healing by recruiting endothelial progenitor cells to the skin of mice that are
hyperglycemic, due to a genetic deletion in the leptin receptor (Leprdb/db) [449]. Intriguingly, diabetic
mice that received folic acid orally showed increased levels of hydroxyproline, a major component of
collagen, and enhanced re-epithelialization, suggesting that folic acid increases collagen turnover and
wound closure [450]. Hydrogen sulfide has also been shown to exert therapeutic effects on wound
healing in Lepob mice, by attenuating inflammation at the injury site [451]. Furthermore, the potential
of mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or amniotic fluid in
treatment of chronic wounds has been widely explored [452]. The therapeutic potential of these cells is
associated with their ability to induce anti-inflammatory responses and secrete proangiogenic agents
and growth factors [452]. In addition, MSCs-derived exosomes carrying miRNA, or growth factors are
currently being explored as potential treatments [453]. These recent advances in diabetic and chronic
wound healing have the potential of bringing novel therapeutic treatments to the clinic.
6.1.2. Burns
Burn injuries are categorized by degrees. A first-degree burn injures the epidermal layer of the
skin, followed by a second-degree, which affects the dermis, and lastly a third-degree injury that
goes as deep as the subcutaneous tissue. Burn injuries are characterized by an intense inflammatory
phase and edema. Blistering is also commonly found in burn patients with second-degree injuries.
However, blistering is absent in murine and porcine skin, which are commonly used as burn injury
animal models.
Severely burned patients usually present a variety of systemic complications, such as depressed
or aggravated immune responses, electrolyte imbalance, sepsis and multiple organ dysfunction
syndrome [454–457], and inflammation-associated psychological effects [458]. In this section, we will
focus on responses that take place locally at the burn wound site and how these affect healing.
In addition to initial damage occurring at the time of the injury, tissue destruction continues
both in size and in depth as a result of extensive secondary necrosis due to impaired vascularization,
free radical formation, and inflammatory mediators [459,460]. The burn site is inundated with
inflammatory mediators and immune cells that exacerbate local tissue damage and further delay
wound closure [461–463]. Inhibition of several cytokines has been shown to promote healing in
burns [464,465].
Immune cells that infiltrate a burn wound are phenotypically the same as those that infiltrate a
non-burn wound. However, it is not clear whether the functionality of the immune cells that enter the
burn wound is the same as those in non-burn wounds. Interestingly, although neutrophils have been
documented to populate burn wounds in high numbers and for prolonged periods of time, studies have
shown that their functions are impaired [466–469]. Activation and migration of neutrophils is essential
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for pathogen clearance at the wound site. Activated neutrophils may also migrate in distal organs
where they exert damaging effects [470–472]. Although depletion of neutrophils leads to increased
infection rates, treatment of rats with resolvin D2 within the first week after burn injury restored
neutrophil migration [473]. In addition, prostaglandin E2 (PGE2) levels at the wound site dictate a
pro-repair neutrophil phenotype [474]. Interestingly, the presence of CD11c+Ly6G+ neutrophil/DC
hybrid cells has been documented in burn wounds [53] with yet undefined roles. The formation of
CD11c+Ly6G+ cells has been observed in other inflammatory conditions in mice, and this subset
may be suggestive of neutrophil plasticity [475]. The mechanism by which neutrophils or neutrophil
subsets influence burn wound healing requires further exploration.
Mast cells are key players in burn injuries and studies have shown they may orchestrate both
the inflammatory and the proliferative phases. They are among the first responders in burn injury
and release histamine and cytokines to promote the inflammatory phase [476]. Deletion of mast cells
reduces tissue damage in a second-degree scald burn injury model in mice [477]. Interestingly, their
numbers are shown to increase after burn injury and reach their peak at later stages, suggesting they
may also be involved in the proliferative phase [478]. It is suggested that mast cells promote tissue
repair and remodeling during the later stages of burn wound healing [478,479]. However, uncontrolled
mast cell activity has been associated with fibrosis and scar formation [57,480].
Monocytes enter the burn site a few days after neutrophils and locally mature to macrophages,
initially exhibiting a pro-inflammatory phenotype. In animal models, a CCR2+ monocyte/macrophage
population is associated with the inflammatory phase, while CX3CR1+ monocyte/macrophage
population is associated with the proliferative phase [481]. Other than secretion of growth
factors [162,163], macrophages also interact with local cells such as fibroblasts to promote healing [482].
Granzyme K expressed by macrophages is elevated in burn patients, and genetic deletion of granzyme
K (GzmK−/−) in mice results in improved healing, suggesting that granzyme K activity in macrophages
plays a major role in burn wound healing [483].
The role of dendritic cells at the wound site is not well delineated. Depletion of all CD11c+ cells
during the early stages post-burn in CD11c-DTR mice resulted in delayed wound healing accompanied
by decreased local cell proliferation and vascularization [53]. However, whether there are specific roles
assigned to dermal dendritic cells subsets in burn injury is still not known.
A burn injury usually results in the formation of an eschar. Blood flow in the tissue underneath
an eschar is restricted resulting in ischemia and further tissue damage [461]. However, hypoxic
environments promote wound closure by adipocyte-derived progenitor cells in an in vitro scratch
wound assay [484]. Burn wounds are characterized by decreased levels of hypoxia-inducible factor
1α (HIF1α) [485]. Interestingly, HIF1α haploinsufficiency results in impaired wound healing in mice
after burn injury, during the later stages of healing and was associated with decreased angiogenesis
compared to HIF1α-sufficient mice [486], corroborating the notion that HIF1α is crucial during the
proliferative stage of burn wound healing. Expression of HIF1α on Tie2+ cells (endothelial and
bone-marrow-derived myeloid cells) mediates the recruitment of angiogenic cells to the burn site as
Tie2Cre-HIF1αfl/fl mice exhibited significantly reduced numbers of de novo generated CD31+ vessels
in the burned wound bed [487]. Additionally, hypoxic monocyte-derived LCs support Th1 responses,
ultimately affect healing progression [488].
T cell responses are dysregulated in burn injuries, likely contributing to impaired healing.
The levels of IL-17 and IL-22, cytokines that support Th17 responses, are significantly elevated in
burned mice when compared to sham controls [489]. The activity of skin-resident γδ T lymphocytes
is also aberrant. While known for their roles in promoting wound healing [72], γδ T cells have been
shown to upregulate expression of the cytokines IFNγ, IL-17, and IL-10 as soon as three days post-burn
in mice, suggesting that γδ T cells perpetuate Th1, Th17, but also regulatory T cell responses in the
burn site [490]. Remarkably, γδ T cells mediate the infiltration of wounds by αβ T cells [491,492], but
αβ T cells in burn wounds exhibit an inactivated phenotype as shown by the decreased expression of
CD69 [492].
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Deregulated proliferative and remodeling phases are commonly seen in burns resulting in scarring
and/or keloid formation (discussed later in this review). However, it has yet to be elucidated whether
this is an independent event or the result of a deregulated inflammatory phase.
Currently, the standard of care for severely burned patients is to undergo autologous split thickness
skin or allograft grafting [461,493]. However, these procedures can lead to complications such as
pain at the grafted site, blood loss, impaired donor skin integration followed by bacterial infection
and inflammation [494,495], and in the case of allograft, rejection. In addition to auto- and allografts,
skin substitutes are also in development [496]. This is an exciting area of research that has produced
promising results. However, the lack of skin elements and innervation in these substitutes can cause
the patient a multitude of complications such as lack of sensation, perspiration and motion flexibility.
Cellular or acellular matrices are also employed, albeit with inconsistent results. Thus, the need for
developing new strategies that promote endogenous healing and tissue reconstruction is dire.
Similar strategies employed for improving healing in chronic wounds have been tested in burn
wounds. Burn wounds treated with umbilical cord-derived MSCs showed improved healing compared
to control wounds [497]. Furthermore, bone-marrow-derived MSCs (BM-MSCs) were shown to migrate
to the site of the burn injury via a CXCR4-CXCL12 signaling axis and improve healing [498]. Many
studies have addressed the role of MSCs in burn wound healing, and some of the pro-healing functions
seem to be increased by ex vivo manipulation such as hypoxic culture and viral transduction for
VEGF, before transplantation [499,500]. Phototherapy is also investigated as a method to promote
burn wound healing. A recent study showed that rats with second-degree burns exhibited faster
healing that was associated with increased levels of autophagy as shown by upregulated LC-3 I and
LC-3 II expression followed by suppression of the inflammasome when the wounds were subjected to
far-infrared phototherapy [501].
Immunological responses in burn injuries differ with age. A clinical study revealed a trend in
which elderly patients expressed higher levels of pro-inflammatory cytokines but contained fewer
macrophage counts in the wound bed when compared to the younger group [502]. Although the
authors did not evaluate the wound re-epithelialization, they did show a trend in which older patients
were associated with a higher burn severity score index when compared to the younger patients.
The sensation of pain in burn injuries may also play a role in controlling local inflammation. It was
recently shown that the TRPV1 nociceptor expressed on sensory nerves in the skin releases CGRP in
response to burn injury, which then regulates the expression of pro-inflammatory cytokines. This effect
can be attenuated when fibulin-5, an extracellular matrix protein found in endothelial and smooth
muscle cells, is overexpressed [503].
7. Wound Complications
Impaired wound healing may lead to severe complications such as local or systemic infections,
neuronal damage, and scarring or keloid formation. We will discuss these complications below.
7.1. Infections
The milieu of non-healing wounds is characterized by deregulated immune responses and as
such, it facilitates colonization of the wounded tissue by pathogenic bacteria [504,505]. Biofilms,
commonly formed in non-healing wounds, are single- or multi-strain communities of microbes
embedded in an extracellular matrix composed of carbohydrates, extracellular DNA, and proteins.
This complex structure confers the biofilm’s resistance to antibiotics and immune responses by
preventing entry of small molecules and immune cells [505–507]. Diabetic wounds are associated
with a variety of antibiotic-resistant bacterial strains [508,509] such as S. aureus, Escherichia coli (E. coli),
Klebsiella, and pathogenic forms of S. epidermidis [504]. Burn patients are also commonly afflicted with
bacterial infections, with the most common strains being Klebsiella pneumoniae, Acinetobacter baumanii,
Pseudomonas aeruginosa, and S. aureus [510–512]. Many of these strains can form biofilms, and if these
infections persist, may lead to bacteremia and ultimately to sepsis [513,514]. Previous studies have
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postulated that the dysregulated immune response in sepsis could be due to simultaneous activation
of pro-inflammatory and anti-inflammatory mechanisms [515,516]. Aftereffects of sepsis may last
for a lifetime if the host survives the initial event. Mice that survived sepsis demonstrated severe
splenomegaly and an elevated population of Ly6C+ inflammatory monocytes [517]. Those who cannot
clear wound infections risk tissue necrosis, potential amputation of the affected extremity, and death
from septic shock.
7.2. Nerve Damage and Chronic Pain
Wounds that are extensive in skin depth usually result in nerve damage. After initial damage,
distal axons degenerate in a process known as Wallerian degeneration. This is followed by formation
of a growth cone, which is usually located at the tip of the proximal bud of the injured nerve. Filipodia
sprout from the growth cone for the regenerating nerve to sample the microenvironment. The path
of the growth cone is affected by the presence of scar tissue in the wound bed, and the growth cone
releases proteases to clear its path [518]. In steady state, sensory nerves require neurotropic factors for
survival and maintenance. These factors are also required for the efficient repair of damaged nerves.
Interestingly, a source of brain-derived neurotropic factor in mice with facial nerve transection was the
cervical lymph nodes, suggesting that immune cells can secrete neurotrophic factors [519]. Schwann
cells in the periphery are important cells in nerve regeneration as they also provide neurotrophic
factors needed to promote regeneration [520]. Remarkably, macrophages have been indicated to play a
role in Schwann cell function after nerve injury [521]. Patients with nerve damage suffer partial or
complete loss of sensory or motor functions in the affected area, numbness, and pain. A transected
nerve can be debilitating for patients who have suffered lacerations as the muscle surrounding the
injured nerve may undergo atrophy if the injured area remains denervated for extended periods of
time, during the healing process [522]. Burn injuries, especially third-degree burns, usually exhibit
nerve damage resulting in complete loss of sensation at the affected site. During nerve repair, the
immune response shifts toward an anti-inflammatory phenotype. Mice with a transected sciatic nerve
exhibited an increase in the mRNA encoding genes associated with anti-inflammatory/pro-reparative
macrophages [523].
Similar to wound healing, the age of the patient may be a factor in the efficient nerve regeneration.
Aged mice with a peripheral nerve crush injury healed slower, exhibited a higher number of Iba1+
macrophages near the affected area, and sustained higher expression of pro-inflammatory markers
when compared to the younger control mice, indicating that aging impairs nerve damage repair [524].
Pain is normally associated with inflammation. However, extensive inflammation and tissue
damage may result in persistent pain, which is associated with alterations in the dorsal root ganglia and
the spinal dorsal horn. In chronic pain, the central nervous system upregulates COX-2 via p38 MAPK
pathway in response to pain due to substance P injection, suggesting that eicosanoids contribute to
chronic pain [525]. TNFα has been shown to reduce the mechanical threshold of C-nociceptors, which
can lead to constant activity and hypersensitivity [526]. Furthermore, TNFα levels are elevated in the
spinal cord after peripheral nerve injury, corroborating the suggestion that inflammatory cytokines
are fundamental to chronic pain [527]. In the spinal cord, the voltage-gated sodium channels Nav1.3,
Nav1.7, and Nav1.8 have been suspected to be active in chronic pain [528]. Patients who suffer from
nerve damage and chronic pain experience lower quality of life due to restrictions in movement,
decreased activity in daily life functions, and increased irritability.
7.3. Hypertrophic Scarring and Keloids
Hypertrophic scarring is the result of overproduction of collagen in the wound bed by fibroblasts.
Scar tissue is characterized by lack of skin elements such as hair follicles and sebaceous glands, and
consequently, stem cells that typically populate these elements [529]. Hypertrophic scarring is common
in burns and cutaneous injuries that affect the dermal layer and may adversely affect the patient’s
quality of life [530].
Int. J. Mol. Sci. 2019, 20, 1811 25 of 53
Hypertrophic scarring can be disfiguring and as such is associated with emotional and mental
effects, and in extreme cases, with self-harm or suicide [531–534]. Scarring can also restrict movement
when occurring in areas such as the hands, knee, elbow, neck, and face [495]. The etiology of
hypertrophic scars is still not well understood. However, it has been shown that it is associated
with reduced collagenase activity, increased presence of myofibroblasts, and high levels of TGFβ and
PDGF [535–537]. Previous studies have shown that fibroblasts in the wound bed exhibit increased
expression of TGFβ and the TGFβ1 receptor, indicating that these cells may be hypersensitive to TGFβ
signaling and thus produce copious amounts of collagen observed in scar tissue [538]. Accordingly,
human fibroblasts in which the TGFβ receptor was knocked down had reduced production of
extracellular matrix components [539].
Intriguingly, macrophages that do not express β-catenin lack the ability to adhere to fibroblasts
and fail to induce TGFβ production, suggesting these macrophages induce scar formation by providing
TGFβ needed to activate fibroblasts [540].
The potential use of stem cells in reducing scarring has been demonstrated as introduction of
BM-MSCs reduced fibrosis in a murine bleomycin-induced fibrosis model [541]. Mast cells have been
implicated in fibrosis and scarring [58–60], making them a potential target for therapies. Polyurethane
scaffolds are also in consideration in the reduction of hypertrophic scars as implantation of a scaffold
in debrided murine burn injuries reduced the rigidity of the formed scar tissue [542].
In humans, keloids are also a common complication characterized as hypertrophic dermal elements.
The collagen content of keloids consists of type III and type I collagen fibers while hypertrophic scars
consist of mostly type III collagen [543,544]. Additionally, hypertrophic scars appear shortly after
injury and may reduce in size over time, while keloid development may lag, and their size can extend
beyond the boundaries of the original wound. Both keloids and hypertrophic scars require TGFβ [545].
Crosstalk between keratinocytes and fibroblasts has been implicated in a previous in vitro study in
which keloid-derived fibroblasts induced the expansion of co-cultured keratinocytes [546].
Current treatments for both hypertrophic scars and keloids involve the use of occlusive dressings
to provide hydration to the affected site, steroid treatment supplemented with compression therapy to
reduce collagen cohesiveness, surgical excision, cryosurgery and radiation therapy [545]. Additionally,
emerging therapies include immunomodulation, botulinum toxin A, hydrogel scaffolds, and skin
tension offloading devices [545].
Another type of treatment that was recently developed and has shown promise, both in promoting
wound healing and reducing scarring, is mechanotherapy. A few of these therapies are silicone gel
sheets, paper tape, and the “Embrace advanced scar therapy” [547]. Silicone gel sheets are used to
reduce tensile stresses in the wound area and maintain hydration to the epidermis, which results in
mediation of the wound cytokine microenvironment [548,549]. Treatment with silicone gel sheets has
also been documented to reduce the expression of TGFβ in fibroblasts [550]. Use of paper tape reduces
wound tension. Paper tape reduced hypertrophic scarring in women who had undergone cesarean
section, compared to women who did not receive treatment [551]. Embrace scar therapy involves
a silicone sheet-based polymer dressing device that is used to apply compressive forces to wound
sites. In a clinical trial conducted by the Gurtner group, patients who were treated with the Embrace
device after undergoing abdominoplasty showed a significant improvement in scar appearance when
compared to patients in the control treatment group [552].
To reduce the scarring or keloid formation in patients, investigators have studied the mechanisms
of scarless healing observed in fetal skin. Previous studies have elucidated a variety of factors that
distinguish fetal from adult wound healing. Fetal wound sites contain fewer inflammatory immune
cells than adult wounds, thus reducing the amount of collateral tissue damage that occurs during
the inflammatory phase of healing [553]. Fetal skin exhibits an increased ratio of type III to type I
collagen in comparison to adult skin [81,553]. Hyaluronic acid is elevated in the fetus [554] and
extracellular matrix components such as fibronectin are more rapidly deposited in the fetal wound
bed [555], suggesting that the microenvironment and resident fibroblasts in fetal wounds are shifted
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toward a regenerative phenotype. As expected, the number of stem cells in the fetal skin is higher
than that in adult skin [556], indicating that regenerative wound healing occurs at a higher frequency
in fetal skin than adult skin. Keratinocytes derived from fetuses that were in the mid-gestation
period of development were shown to induce the expression of MMPs and collagen production from
mature fibroblasts when co-cultured in vitro [557], revealing a potential role of the crosstalk between
keratinocytes and fibroblasts in reducing scar formation.
8. Conclusions
The skin is the largest organ and is in constant contact with the environment. To protect the
host from infection, it has developed a variety of defensive strategies. In addition to physical,
microbiological, and chemical barriers, the skin contains resident immune cells that serve sentinel
functions and contribute to tissue homeostasis. In the event of an insult, these cells act in harmony to
locally initiate inflammatory responses, and if needed, to prime adaptive immunity.
Despite intensive research in the wound healing field, we have yet to fully understand the
mechanisms that promote this process. Impaired wound healing gives rise to complications such as
persistent infections, neuronal damage, and pain. Additionally, dysregulated inflammatory responses
contribute to uncontrolled skin cells proliferation leading to fibrosis. Recent research has delved
into the mechanisms of impaired wound healing and uncovered the potential for exploiting cellular
and molecular targets for the development of novel therapeutics in hopes of accelerating the healing
of chronic wounds. In addition to the approaches discussed in this review, a new approach is the
modulation of wound microbiome, discussed elsewhere [558–560]. In view of the challenges associated
with management of chronic and inflammatory wounds, it is clear that new strategies are needed.
Understanding the cellular and molecular interactions between immune cells and skin-resident
cells is necessary to delineate the dynamics of wound repair.
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